Scientists launch massive GIST registry to unlock secrets of rare cancer

NCT ID NCT07273045

Not yet recruiting Knowledge-focused Sponsor: Universität Duisburg-Essen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This registry study will collect medical information and biological samples from 1,000 people with gastrointestinal stromal tumors (GIST), a rare type of digestive tract cancer. The goal is to better understand how GIST behaves, especially in rare forms, and to identify factors that lead to treatment resistance or recurrence. No new treatments or extra procedures are involved—participants continue their usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this registry could help researchers identify risk factors and design better treatments for rare forms of GIST.
What could go wrong: This is an observational registry, not a treatment trial. It will not directly benefit participants and may take years to yield useful results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTENSTINAL STROMAL TUMOR (GIST) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTENSTINAL STROMAL TUMOR (GIST) GIST - GASTROINTESTINAL STROMAL TUMOR

Contacts and locations

Locations

University Hospital Essem

Essen, North Rhine-Westphalia, 45147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.